关键词: 癫痫, 吡仑帕奈, 单药, 疗效, 安全性

Abstract: Perampanel(PER), as the first highly selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxy-5-methyl -4-isooxazolpropionic acid (AMPA) receptor antagonist approved for use, is currently approved in China for the treatment of focal epilepsy (with or without progression to bilateral tonic-clonic seizures) in adults and children aged 4 years and older. This drug was marketed late in China, and was mostly used for additive therapy in adults and children. There is little experience in the application of monotherapy for children's epilepsy. This article reviewed the mechanism of action, pharmacokinetics, efficacy and safety of PER in the treatment of childhood epilepsy at home and abroad, in order to provide reference for clinicians. 

Key words:

Epilepsy, Perampanel, Monotherapy, Efficacy, Safety